Chongqing Key Laboratory of Infectious Diseases and Parasitic Diseases, Department of Infectious Diseases, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
J Med Virol. 2013 Jun;85(6):1077-84. doi: 10.1002/jmv.23546.
Replication-defective adenoviruses have been utilized as candidate vaccine vectors. However, clinical application of the best-studied human adenovirus type-5 (AdHu5) is limited by the high prevalence of preexisting neutralizing antibodies resulting from natural infection. Therefore, rare adenovirus serotypes, such as human adenovirus type-26 (AdHu26) and chimpanzee adenovirus type-68 (AdC68), have been employed as substitutes for AdHu5. However, few studies have described the epidemiology of pre-existing immunity to these adenoviruses in China. Thus, 1,154 participants from six regions in China were examined to assess the presence of neutralizing antibodies against AdHu5, AdHu26, and AdC68. The seroprevalence rates of neutralizing antibodies were as follows: AdHu5, 73.1% (844/1,154) (95% confidence interval: 70.5-75.6%); AdHu26, 35.3% (407/1,154) (95% confidence interval: 32.6-38.1%); and AdC68, 12.7% (147/1,154) (95% confidence interval: 10.9-14.8%), respectively. The most frequently detected and highest titer antibodies were specific for AdHu5. The results indicate that AdHu26 and AdC68 serve as more suitable vaccine vectors than AdHu5.
复制缺陷型腺病毒已被用作候选疫苗载体。然而，研究最多的人类腺病毒 5 型（AdHu5）的临床应用受到由于自然感染而导致的预先存在的中和抗体的高流行率的限制。因此，已经使用稀有腺病毒血清型，如人类腺病毒 26 型（AdHu26）和黑猩猩腺病毒 68 型（AdC68）作为 AdHu5 的替代品。然而，很少有研究描述过中国这些腺病毒预先存在的免疫情况的流行病学。因此，检查了来自中国六个地区的 1154 名参与者，以评估针对 AdHu5、AdHu26 和 AdC68 的中和抗体的存在情况。中和抗体的血清阳性率如下：AdHu5，73.1%（844/1154）（95%置信区间：70.5-75.6%）；AdHu26，35.3%（407/1154）（95%置信区间：32.6-38.1%）；和 AdC68，12.7%（147/1154）（95%置信区间：10.9-14.8%）。最常检测到和最高滴度的抗体是针对 AdHu5 的特异性抗体。结果表明，AdHu26 和 AdC68 比 AdHu5 更适合作为疫苗载体。
